TITLE

Amphotericin B: an antifungal drug in nanoformulations for the treatment of paracoccidioidomycosis

AUTHOR(S)
Garcia, Mônica Pereira; de Fátima Menezes Almeida Santos, Maria; Saldanha, Camila Arruda; Iocca, Diêgo Cesar; Azevedo, Ricardo Bentes
PUB. DATE
September 2013
SOURCE
Revista Salud UIS;2013, Vol. 45 Issue 3, p45
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The use of magnetic nanoparticles (MNPs) in drug delivery vehicles must address issues such as drugloading capacity, desired release profile, aqueous dispersion stability, biocompatibility with cells and tissue, and retention of magnetic properties after interaction with macromolecules or modification via chemical reactions. Amphotericin B (AmB) is still the first choice for the treatment of severe paracoccidioidomycosis, an important systemic fungal infection caused by Paracoccidoides brasiliensis. Unfortunately, AmB causes acute side effects (mainly urinary problems) following intravenous administration, which limits its clinical use. The use of magnetic nanoparticles stabilized with biocompatible substances, together with the possibility of their conjugation with drugs has become a new nanotechnological strategy in the treatment of diseases for drug delivery to specific locations, such as the lungs in paracoccidoidiodomycosis. This review provides an overview of the disease, its etiologic agent and treatment with emphasis on the main strategies to improve the use of AmB in nanoformulations.
ACCESSION #
95511534

 

Related Articles

  • Susceptibility of fungi isolated from the respiratory tract of falcons to amphotericin B, itraconazole and voriconazole. Silvanose, C. D.; Bailey, T. A.; Di Somma, A. // Veterinary Record: Journal of the British Veterinary Association;8/26/2006, Vol. 159 Issue 9, p282 

    The minimum inhibitory concentrations (MICs) of fungi isolated from the air sacs of falcons before (group 1), and during antifungal treatment with amphotericin B nebulisation and oral itraconazole or voriconazole (group 2), or with itraconazole alone (group 3) or voriconazole alone (group 4)...

  • Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Playford, E. G.; Webster, A. C.; Sorrell, T. C.; Craig, J. C. // European Journal of Clinical Microbiology & Infectious Diseases;Sep2006, Vol. 25 Issue 9, p549 

    A systematic review and meta-analysis was performed to evaluate the benefits and harms of antifungal prophylaxis in liver transplant recipients. Ten randomised trials comparing any prophylactic antifungal regimen with no antifungal agent or with another antifungal regimen were identified from...

  • Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital. Miranda-Zapico, Ilargi; Eraso, Elena; Hernández-Almaraz, José Luis; López-Soria, Leyre Mónica; Carrillo-Muñoz, Alfonso Javier; Hernández-Molina, Juan Manuel; Quindós, Guillermo // Journal of Antimicrobial Chemotherapy (JAC);Oct2011, Vol. 66 Issue 10, p2315 

    Objectives There is scarce information on the clinical relevance and antifungal susceptibility of Candida bracarensis, Candida nivariensis, Candida orthopsilosis and Candida metapsilosis. The objective of this study was to assess the prevalence and in vitro antifungal susceptibility of these...

  • Quantitative and Qualitative Analysis of the Antifungal Activity of Allicin Alone and in Combination with Antifungal Drugs. Young-Sun Kim; Kyung Sook Kim; Ihn Han; Mi-Hyun Kim; Min Hyung Jung; Hun-Kuk Park // PLoS ONE;Jun2012, Vol. 7 Issue 6, p1 

    The antifungal activity of allicin and its synergistic effects with the antifungal agents flucytosine and amphotericin B (AmB) were investigated in Candida albicans (C. albicans). C. albicans was treated with different conditions of compounds alone and in combination (allicin, AmB, flucytosine,...

  • Surface Response Modeling to Examine the Combination of Amphotericin B Deoxycholate and 5-Fluorocytosine for Treatment of Invasive Candidiasis. Hope, William W.; Warn, Peter A.; Sharp, Andrew; Reed, Paul; Keevil, Brian; Louie, Arnold; Denning, David W.; Drusano, George L. // Journal of Infectious Diseases;8/15/2005, Vol. 192 Issue 4, p673 

    The strategy of combining antifungal drugs in a treatment regimen may improve the outcome of invasive candidiasis. Using a well-validated pharmaco dynamic murine model of invasive candidiasis, we defined the effect of the combination of amphotericin B deoxycholate (AmB) and 5-fluorocytosine...

  • Clinical Pharmacokinetics of Systemically Administered Antimycotics. Bellmann, Romuald // Current Clinical Pharmacology;Jan2007, Vol. 2 Issue 1, p37 

    Systemic fungal infections are a major threaten for immunocompromised patients. Beside the antimycotic spectrum, the pharmacokinetic properties of an antifungal drug are crucial for its clinical efficacy. Since patients with systemic mycoses frequently present with a significant co-morbidity,...

  • Antifungal Combination Therapy: Clinical Potential. Baddley, John W.; Pappas, Peter G. // Drugs;2005, Vol. 65 Issue 11, p1461 

    Combination antifungal therapy has been an area of research and clinical interest since systemic antifungals became available decades ago. In vitro and clinical data were generated for some of the more common invasive fungal infections, especially candidiasis, but until very recently few...

  • Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries. Ullmann, Andrew J.; Sanz, Miguel A.; Tramarin, Andrea; Barnes, Rosemary A.; Wu, Wenchen; Gerlach, Barbara A.; Krobot, Karl J.; Gerth, William C. // Clinical Infectious Diseases;8/15/2006, Vol. 43 Issue 4, pe29 

    Background. Amphotericin B is a widely used broad-spectrum antifungal agent, despite being associated with significant adverse events, including nephrotoxicity. Methods. The present prospective study collected data on outcomes for 418 adult patients treated consecutively with polyenes in...

  • Amphotericin B/amphotericin B liposomal.  // Reactions Weekly;Oct2015, Vol. 1572 Issue 1, p24 

    The article presents a case study of a 49-year-old female patient who developed nephrotoxicity during treatment with amphotericin B and amphotericin B liposomal.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics